IBDEI0MR ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,10390,1,4,0)
 ;;=4^E05.91
 ;;^UTILITY(U,$J,358.3,10390,2)
 ;;=^5002493
 ;;^UTILITY(U,$J,358.3,10391,0)
 ;;=E89.0^^68^667^50
 ;;^UTILITY(U,$J,358.3,10391,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10391,1,3,0)
 ;;=3^Postprocedural Hypothyroidism
 ;;^UTILITY(U,$J,358.3,10391,1,4,0)
 ;;=4^E89.0
 ;;^UTILITY(U,$J,358.3,10391,2)
 ;;=^5003035
 ;;^UTILITY(U,$J,358.3,10392,0)
 ;;=E03.2^^68^667^32
 ;;^UTILITY(U,$J,358.3,10392,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10392,1,3,0)
 ;;=3^Hypothyroidism d/t Meds/Oth Exogenous Substances
 ;;^UTILITY(U,$J,358.3,10392,1,4,0)
 ;;=4^E03.2
 ;;^UTILITY(U,$J,358.3,10392,2)
 ;;=^5002471
 ;;^UTILITY(U,$J,358.3,10393,0)
 ;;=E03.9^^68^667^33
 ;;^UTILITY(U,$J,358.3,10393,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10393,1,3,0)
 ;;=3^Hypothyroidism,Unspec
 ;;^UTILITY(U,$J,358.3,10393,1,4,0)
 ;;=4^E03.9
 ;;^UTILITY(U,$J,358.3,10393,2)
 ;;=^5002476
 ;;^UTILITY(U,$J,358.3,10394,0)
 ;;=E06.0^^68^667^53
 ;;^UTILITY(U,$J,358.3,10394,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10394,1,3,0)
 ;;=3^Thyroiditis,Acute
 ;;^UTILITY(U,$J,358.3,10394,1,4,0)
 ;;=4^E06.0
 ;;^UTILITY(U,$J,358.3,10394,2)
 ;;=^2692
 ;;^UTILITY(U,$J,358.3,10395,0)
 ;;=E06.1^^68^667^54
 ;;^UTILITY(U,$J,358.3,10395,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10395,1,3,0)
 ;;=3^Thyroiditis,Subacute
 ;;^UTILITY(U,$J,358.3,10395,1,4,0)
 ;;=4^E06.1
 ;;^UTILITY(U,$J,358.3,10395,2)
 ;;=^119376
 ;;^UTILITY(U,$J,358.3,10396,0)
 ;;=C73.^^68^667^37
 ;;^UTILITY(U,$J,358.3,10396,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10396,1,3,0)
 ;;=3^Malig Neop of Thyroid Gland
 ;;^UTILITY(U,$J,358.3,10396,1,4,0)
 ;;=4^C73.
 ;;^UTILITY(U,$J,358.3,10396,2)
 ;;=^267296
 ;;^UTILITY(U,$J,358.3,10397,0)
 ;;=E10.21^^68^667^8
 ;;^UTILITY(U,$J,358.3,10397,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10397,1,3,0)
 ;;=3^DM Type 1 w/ Diabetic Nephropathy
 ;;^UTILITY(U,$J,358.3,10397,1,4,0)
 ;;=4^E10.21
 ;;^UTILITY(U,$J,358.3,10397,2)
 ;;=^5002589
 ;;^UTILITY(U,$J,358.3,10398,0)
 ;;=E10.9^^68^667^12
 ;;^UTILITY(U,$J,358.3,10398,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10398,1,3,0)
 ;;=3^DM Type 1 w/o Complications
 ;;^UTILITY(U,$J,358.3,10398,1,4,0)
 ;;=4^E10.9
 ;;^UTILITY(U,$J,358.3,10398,2)
 ;;=^5002626
 ;;^UTILITY(U,$J,358.3,10399,0)
 ;;=E11.21^^68^667^17
 ;;^UTILITY(U,$J,358.3,10399,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10399,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Nephropathy
 ;;^UTILITY(U,$J,358.3,10399,1,4,0)
 ;;=4^E11.21
 ;;^UTILITY(U,$J,358.3,10399,2)
 ;;=^5002629
 ;;^UTILITY(U,$J,358.3,10400,0)
 ;;=E11.39^^68^667^18
 ;;^UTILITY(U,$J,358.3,10400,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10400,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Ophthalmic Complication NEC
 ;;^UTILITY(U,$J,358.3,10400,1,4,0)
 ;;=4^E11.39
 ;;^UTILITY(U,$J,358.3,10400,2)
 ;;=^5002643
 ;;^UTILITY(U,$J,358.3,10401,0)
 ;;=E11.43^^68^667^15
 ;;^UTILITY(U,$J,358.3,10401,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10401,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Autonomic Neuropathy
 ;;^UTILITY(U,$J,358.3,10401,1,4,0)
 ;;=4^E11.43
 ;;^UTILITY(U,$J,358.3,10401,2)
 ;;=^5002647
 ;;^UTILITY(U,$J,358.3,10402,0)
 ;;=E11.59^^68^667^13
 ;;^UTILITY(U,$J,358.3,10402,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10402,1,3,0)
 ;;=3^DM Type 2 w/ Circulatory Complications NEC
 ;;^UTILITY(U,$J,358.3,10402,1,4,0)
 ;;=4^E11.59
 ;;^UTILITY(U,$J,358.3,10402,2)
 ;;=^5002652
 ;;^UTILITY(U,$J,358.3,10403,0)
 ;;=E11.618^^68^667^14
 ;;^UTILITY(U,$J,358.3,10403,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10403,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Arthropathy NEC
 ;;^UTILITY(U,$J,358.3,10403,1,4,0)
 ;;=4^E11.618
